Basic information
- CAS
1263-89-4- Standard SMILES
NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O.O=S(=O)(O)O- InChIKey
LJRDOKAZOAKLDU-UDXJMMFXSA-N- Molecular formula
- C23H47N5O18S
- Average molar mass
- 713.7 g/mol
- Monoisotopic mass
- 713.26368084
Names & identifiers
- Preferred name
- Paromomycin Sulfate
- IUPAC
- (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric acid
- English name
- PAROMOMYCIN SULFATE
- Molecular formula
- C23H47N5O18S
- Molecular weight
- 713.71
Names & synonyms
Show more names
Database identifiers
- CAS
1263-89-4、7205-49-4- PubChem CID
- 441375
- DTXSID
DTXSID601335979- ChEMBL
CHEMBL2206196- ChEBI
CHEBI:7935- UNII
- 845NU6GJPS
- EC Number
- 215-031-7、230-575-5
Properties
Computed structural properties
- Topological polar surface area
- 430 Ų
- Hydrogen bond donors
- 15
- Hydrogen bond acceptors
- 23
- Rotatable bonds
- 9
- Heavy atoms
- 47
- Formal charge
- 0
- Complexity
- 952
Physicochemical properties
- Melting point
- 145 °C · 145 °C (decomp)
- alpha
- 25 · D25 +50.5° (c = 1.5 in water pH 6)
- storage temp.
- Keep in dark place,Inert atmosphere,Room temperature
- solubility
- 2 O: · H2O: 50 mg/mL store stock solution at 2-8°C. Stable at 37°C for 5 days.
- form
- powder
- color
- White to Off-White
- Water Solubility
- Soluble in water
- Merck
- 14 · 14,7041
- BRN
- 5715182 · 5715182
- Stability
- Hygroscopic
- InChIKey
- LJRDOKAZOAKLDU-UDXJMMFXSA-N
- CAS DataBase Reference
- 1263 · 1263-89-4
- FDA UNII
- 845 NU6GJPS · 845NU6GJPS
- NCI Drug Dictionary
- Humatin
- EPA Substance Registry System
- Paromomycin sulfate (1263-89-4)
- UNSPSC Code
- 12352200 · 12352200
- NACRES
- 72 · NA.72
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 315 · H315-H319-H335
- Precautionary statements
- 261 · P261-P280a-P304+P340-P305+P351+P338-P405-P501a
- Hazard Codes
- Xi
- Risk Statements
- 23 · 23/24/25-36/38-39/23/24/25-61-36/37/38
- Safety Statements
- 26 · 26-36/37-45-38-36
- WGK Germany
- 2 · 2
- RTECS
- 2320000 · WK2320000
- HS Code
- 2941901010 · 2941901010
- Storage Class
- 11 · 11 - Combustible Solids
- Toxicity
- 50 in · LD50 in mice (mg/kg): ~15,000 orally; 700 s.c.; 110 i.v. (Di Marco, Bertazzoli)
Safety & regulation
GHS classification
GHS Classification
This chemical does not meet GHS hazard criteria for 93% (53 of 57) of all reports.
Not Classified;Reported as not meeting GHS hazard criteria by 53 of 57 companies (only 7% companies provided GHS information). For more detailed information, please visit ECHA C&L website.
Aggregated GHS information provided per 57 reports by companies from 5 notifications to the ECHA C&L Inventory.;Reported as not meeting GHS hazard criteria per 53 of 57 reports by companies.;There are 4 notifications provided by 4 of 57 reports by companies with hazard statement code(s).;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Hazard information
Toxicology
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Paromomycin sulfate
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation;No information is available on the clinical use of paromomycin during breastfeeding. Because paromomycin is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants.;◉ Effects in Breastfed Infants;Relevant published information was not found as of the revision date.;◉ Effects on Lactation and Breastmilk;Relevant published information was not found as of the revision date.
Regulatory information
Safety data
- wgk
- 2
- rtecs
- WK2320000
- hs_code
- 2941901010
- Toxicity
- LD50 in mice (mg/kg): ~15,000 orally; 700 s.c.; 110 i.v. (Di Marco, Bertazzoli)
- risk_code
- 23/24/25-36/38-39/23/24/25-61-36/37/38
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- hazard_code
- Xi
- safety_code
- 26-36/37-45-38-36
- Storage Class
- 11 - Combustible Solids
- Hazard statements
- H315-H319-H335
- Precautionary statements
- P261-P280a-P304+P340-P305+P351+P338-P405-P501a
Chemistry & industry
Pharmacology
FDA Pharmacological Classification
PAROMOMYCIN SULFATE
Antiprotozoal [EPC]
MeSH Pharmacological Classification
Substances that are destructive to protozoans.
Substances that inhibit the growth or reproduction of BACTERIA.
Applications
DescriptionParomomycin was found in the culture broth of Streptomyces rimosus forma paromomycinus by Parke Davis & Co. in 1959. In the same year it was found in the culture broth of S. Crestomyceticus by Farmitalia and named amminosidin. Paromomycin is related structurally to neomycin, but it has a hydroxyl group at the 6 position, whereas neomycin has an amino group. Its antibacterial activity is weaker than that of neomycin, but its toxicity is much less. Paromomycin is used by intramuscular injection for therapy of respiratory, urinary, and surgical infections and by oral administration to treat dysentery and salmonellosis.
UsesPAROMOMYCIN SULFATE is an aminogycoside antibiotic designed to fight intestinal infections such as cryptosporidiosis, amoebiasis, and leishmaniasis. Its antiprotozoal activity makes it an effecive histomonostatic feed addit ive in turkey poults experimentally infected with Histomonas meleagridis.
Usesantibacterial, antiamebic
Usespolymeric nonionic detergent
General DescriptionChemical structure: aminoglycoside
Suppliers105 total
Additional notes
DefinitionChEBI: An aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoa infections. It is also used as a therapeutic against visceral leishmaniasis.
Related reactions
Compound notes
Loading…